Other Events ·
Vicore Pharma's Phase 2b ASPIRE trial of buloxibutid in IPF passes futility analysis and continues
VCREVicore Pharma Holding AB
The independent Data Monitoring Committee for Vicore Pharma Holding AB's Phase 2b ASPIRE trial recommended the study continue without modification after a pre-planned futility analysis. The trial, which enrolled 378 patients with idiopathic pulmonary fibrosis, assessed the change from baseline in forced vital capacity at Week 52 for buloxibutid versus placebo. No safety concerns were identified during the review of data from approximately 100 randomized patients who completed 52 weeks of treatment or discontinued. The company remains blinded to quantitative results and expects topline results in mid-2027, with cash runway extending into the second half of 2028. Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing angiotensin II type 2 receptor agonists for respiratory and fibrotic diseases.